

# Functional assessment (invasive) of Coronary Circulation

Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium



## Potential conflicts of interest

- Consulting fees and honoraria on my behalf go to the Cardiovascular Research Center Aalst
- Contracted Research between the Cardiovascular Research Center Aalst and the following pharmaceutical and device companies:

Ablynx, Astra Zeneca, BMS, Eli Lilly, GSK, Therabel, Abbott Vascular, Biotronik, Boston Scientific, Cordis J&J, Edwards, Medtronic, Orbus Neich, St Jude, Terumo

 Ownership Interest: Cardiovascular Research Center Aalst is cofounder of Cardio<sup>3</sup>BioSciences, a start-up company focusing on cellbased regenerative cardiovascular therapies



## Why do we need functional assessment?



### Event Rates after a Negative Functional Stress Testing Myocardial Perfusion Imaging or Stress Echocardiography


Table 4

Summary Estimates of Rates After a Negative Test and Negative Predictive Value for Myocardial Infarction or Cardiac Death for Women and Men in Exercise Myocardial Perfusion Imaging and Exercise Echo

Exercise Imaging Modality	n	Mean Follow-Up (Months)	Summary Event Rate After Negative Test (%) (95% CI)	Negative Predictive Value (%) (95% CI)	Annualized Event Rate (%)
MPI	Myocardial Perfusion Imaging				
All	2,900	32	1.03 (0.70-1.48)	99.0 (98.5-99.3)	0.58
Women	1,443	32	0.69 (0.33-1.27)	99.3 (98.7-99.7)	0.33
Men	1,457	20	1.37 (0.84-2.12)	98.6 (97.9-99.2)	0.82
Echo	Stress Echocardiography				
All	5,946	37.6	3.23 (2.70-3.82)	96.8 (96.2-97.3)	1.03
Women	2,547	37.6	2.34 (1.71-3.13)	97.7 (96.9-98.3)	0.75
Men	3,399	37.6	3.90 (3.12-4.81)	96.1 (95.2-96.9)	1.24




## Annual risk of Cardiac Death and Myocardial Infarction




## Extent of Functional Assessment abnormality and Cardiovascular Event Rate

- 314 patients with CAD
- either PCI+OMT After - or OMT
- Myocardial perfusion imaging prior and again 6 months after treatment




## SWISSI II Trial 201 patients with silent ischemia after a myocardial infarction 10 Year-Follow-Up





## Freedom from Chest-pain



Ischemic lesions (FFR < 0.75) treated by stenting



European Heart Journal (2010) 31, 2501-2555 doi:10.1093/eurhearti/ehg277





### Guidelines on myocardial revascularization


The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)

Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI)‡

Authors/Task Force Members: William Wijns (Chairperson) (Belgium)\*, Philippe Kolh

... In summary, documentation of ischaemia using functional testing is strongly recommended before elective invasive procedures, preferably using non-invasive testing before invasive angiography


## Frequency of stress tests to document ischemia prior to elective CAG+PCI



23887 Medicare patients undergoing elective CAG+PCI in 2004



## Referral to CAG after the initial consultation



### Countries with Low Rate of CAG


- Positive Exercise Test
- Female Gender

### **Countries with High Rate of CAG**

- Positive Exercise Test
- Female Gender
- Invasive Centre
- Symptom duration > 6 months



## Frequency of Stress Testing to Document Ischemia Prior to Elective CAG+PCI




23887 Medicare patients undergoing elective CAG+PCI in 2004

### Functional assessment of coronary circulation











## Clinical conditions in which non-invasive testing Is difficult to interpret


- 1. During and after acute myocardial infarction
- 2. Obesity, bundle branch block, ...
- 3. "Intermediate lesion"
- 4. Left main stenosis
- 5. Multivessel disease
- 6. ...

## Diagnostic accuracy of ECG-gated SPECT MPI in patients 3-vessel disease










How to proceed?
It is not the question <u>IF</u> stenting is indicated, but <u>WHERE</u> and <u>HOW MANY</u>



## 2D and 3D QCA








### 

Years

### Intermediate-to-high Risk




COURAGE W.E. Boden et al NEJM 2007


SYNTAX F.W. Mohr et al Lancet 2013

Survival Free of Death from Any Cause and Myocardial


## Relationship between %DS and coronary flow




## Relationship between %DS and coronary flow




## Relationship between %DS and coronary flow



## **Anatomy vs Physiology: the Chimeric Link**






Statistical (mechanistic) relation but little clinical relation

## A COLAR CETA

## **Fractional Flow Reserve**

FFR = ratio of hyperemic flow in the stenotic vessel to hyperemic flow in the same vessel but in the absence of the stenosis

FFR = extent to which (%) maximal myocardial flow is limited by the epicardial stenosis




$$FFR = \frac{Q_{max}^{S}}{Q_{max}^{N}} = \frac{P_d}{P_a}$$

## **During maximal hyperemia**

(i.e. during maximal transstenotic flow)




## The relation between $P_d/P_a$ and $Q_s/Q_N$ is LINEAR during HYPEREMIA






## The relation between $P_d/P_a$ and $Q_s/Q_N$ is LINEAR during HYPEREMIA

- 22 Patients with an isolated proximal LAD stenosis
- H<sub>2</sub><sup>15</sup>O PET maximal flow in LAD vs normal territories
- FFR within 24 hours






## Validation of FFR in Humans (Step 1)



Proper validation of any index needs 2 steps:

- Searching for the threshold value in a selected population (sens, specif, NPV, PPV, ROC analysis)
- 2. Prospective validation in a population with unknown characteristics

Pijls et al, Circulation 1995 De Bruyne, Circulation 1996



### Testing of FFR versus True Gold Standard



Creating a gold standard by **Prospective Multitesting Sequential Bayesian Approach:** 

- Exerc testing = electrical index of ischemia
- MIBISpect = perfusion index of ischemia
- Dobutrex Echo = contractile index of ischemia
- reversal from positive before to negative after intervention, proves true positivity before and true negativity after test


### Diagnostic accuracy of FFR =

$$[(1-0.75) \times (1-0.8) \times (1-0.8)]^{-1} = 99 \%$$

3 unclassifiable patients (no intervention)
→ worst case scenario for FFR → 93 %

Pijls et al, NEJM 1996

## Threshold value of FFR to detect significant stenosis in humans



FFR is the **only** functional index which has ever been validated versus a **true gold standard**. (Prospective multi-testing Bayesian methodology)

<u>ALL</u> studies ever performed in a wide variety of clinical & angiographic conditions, found threshold between 0.75 and 0.80

Diagnostic accuracy > 93%

Pijls et al, N Engl J Med 1996; 334:1703-1708 Oldroyd et al, Circulation 2010




### **Clinical Outcome**

In stable patients with single vessel disease, stenting functionally non-significant stenoses does not improve clinical outcome as compared to deferring these stenoses to optimal medical treatment
 DEFER trial

## SECULAR CONTRACTOR

## **DEFER: Clinical Outcome at 5 Years**

Rate of Death/MI after 5 years






### **Clinical Outcome**

- In stable patients with single vessel disease, stenting functionally non-significant stenosis does not improve clinical outcome as compared to deferring these stenoses to optimal medical treatment
   DEFER trial
- In patients with multivessel disease, an FFR-guided PCI strategy improves clinical outcome as compared with an Angio-guided strategy
   FAME trial




## **FAME** trial





## **FAME** trial






## **Clinical Outcome**

- In stable patients with single vessel disease, stenting functionally non-significant stenosis does not improve clinical outcome as compared to deferring these stenoses to optimal medical treatment.
- In patients with multivessel disease, an FFR-guided PCI strategy improves clinical outcome as compared with an Angio-guided strategy.
- In stable patients with at least one functional significant stenosis, FFR-guided PCI plus MT is associated with better clinical outcome as compared with MT alone.
  - → FAME 2 trial




## **FAME 2 TRIAL Primary End Point**





### **FAME 2: 607 Patients on Medical Therapy**

(1027 lesions, Median FU= 191 days)



Actual FFR value predicts the natural history of stenoses in patients with stable coronary disease



### Take-home messages

- Evidences of a beneficial clinical outcome with FFR-guided revascularization strategy in different angiographic settings:
  - Isolated equivocal left main stenosis (n=230+51)
    - Hamilos, Circ 2009/Lindstaedt, Am Heart J 2006
  - Isolated prox left anterior descending artery (n=72)
    - Muller, JACC Cardiovasc Int
  - Small vessel disease (n=717)
    - Puymirat, Circ
  - By-pass grafts (n=
  - 000 patients Bifur

2008/Kumsars, Eurointy 2012

n=131) Seria

Kim, JACC Cardiovasc Intv 2012

- Drug Eluting Stent Restenosis (n=49)
  - → Nam, Am J Cardiol 2011
- Post-stenting (BMS and DES) (n=750+80)
  - Pijls NHJ, Circ 2002/Nam, Am J Cardiol 2011
- All comers, contemporary practice (n=7358)
  - Li J, EHJ 2013



### Level of Evidence of FFR

 FFR-guided PCI is recommended for detection of ischaemia-related lesion(s) when objective evidence of vessel-related ischaemia is not available

Class of Recommendation: I

Level of Evidence: A



### **New Diagnostic Strategies**

RIPCORD study


French registry

POST-IT



### French registry

1075 consecutive patients undergoing diagnostic CAG



Change of Revascularization Strategy in 43% of the patients



### **New Therapeutic Strategies**

CABG registry


GRAFFITI trial

FAME 3 trial

Ste CULAR CENTER

Angio-guided n=429 FFR-guided n=198

### Clinical endpoints @ 36 months




FFR: 198

135 Toth G. et al. Circulation 2013

190

## STATE OF THE PARTY OF THE PARTY

### CCS II-IV @ 36 months





### GRAFFITI trial: GRaft Patency After FFR-guided vs Angio-guided CABG: a randomized clinical Trial


PI: Emanuele Barbato MD, PhD
Cardiovascular Center Aalst, Belgium

### **Hypothesis**

FFR-guided CABG is associated with a lower rate of 1-year graft occlusion




### GRAFFITI trial: GRaft Patency After FFR-guided vs Angio-guided CABG: a randomized clinical Trial



### E COLAR COLOR COLAR COLA

### FAME 3: A Comparison of FFR-guided PCI and CABG in Patients with Multivessel Coronary Artery Disease



#### **Hypothesis:**

FFR-guided PCI in MVD will result in similar outcomes to CABG

#### **Design:**

- Noninferiority design
- Clinically relevant difference of 5%

#### Pl's:

- Fearon WF (PI)
- Pijls NHJ (Co-PI)
- De Bruyne B (Co-PI)

Cardiology Forum, Rome 2014



# Can we obtain the same results but simplifying the technique?



- Adenosine-free pressure derived coronary functional indexes:
  - bSR (Piek)
  - iFR (Davies)
  - iFG (Indolfi)
  - Pd/Pa (Mammhas)
- Non-invasive FFR:
  - FFR<sub>CT</sub>



### Accepted Manuscript



Multicenter Core Laboratory Comparison of the Instantaneous Wave-Free Ratio and Resting  $P_d/P_a$  with Fractional Flow Reserve: The RESOLVE Study

Allen Jeremias, MD, N Asrress, MA, BM BCh Bernard De Bruyne, MD Justin E.

Davies, MBBA Javier Leganou, MD villian I. I caron, MD 18. Lanco Coula, MD 1815
Marques,


Davies, MBBA Javier Escaned, etraco, hD Jos

A.E. Spaa MD

MD Jan J. Piek, MD Nico H. Pijls,




### Correlation between Pd/Pa and iFR






### Moderate diagnostic accuracy





- Adenosine-free pressure derived coronary functional indexes:
  - bSR (Piek)
  - iFR (Davies)
  - iFG (Indolfi)
  - Pd/Pa (Mammhas)
- Non-invasive FFR:
  - FFR<sub>CT</sub>


### FFR<sub>CT</sub> From Anatomy to function



- 1. Coronary flow meets myocardial demand at rest
- 2. Resistance of microcirculatory vascular bed at rest is inversely proportional to size of feeding vessel
- 3. Microcirculation has a predictable response to adenosine

### **Computational Flow Dynamics**






1. Min et al.

JAMA 2012;308:1237-1245


### SECULAR CONTRACTOR

### Diagnostic Accuracy of FFR<sub>CT</sub>: DeFacto

#### **Per-Patient**




### **Before/After Stenting**




Diagnostic accuracy ≈ 80%



## FFR is the gold standard to assess ischemia



























#### **Features of IMR**

- Specific for the microvasculature
- Quantitative and reproducible
- Predictive of outcomes
- Independent from changes in heart rate, blood pressure and contractility (Ng, Circulation 2006)





### **Derivation of IMR**

• Resistance =  $\triangle$  Pressure / Flow

• 1 / Tmn @ Flow

• IMR = Distal Pressure / (1 / Tmn)

• IMR = Distal Pressure x Tmn at maximal hyperemia

Note: Must incorporate coronary wedge pressure to account for collateral flow if significant epicardial stenosis is present




### Clinical use of IMR

- Assessment of myocardial perfusion in STEMI patients
- Predictive of left ventricular remodeling after primary PCI

### Assessment of myocardial perfusion in STEMI patients

41 STEMI pts randomized either to pPCI plus IC STPK or pPCI alone




Sezer M, NEJM 2007



### Predictive value after primary PCI

29 STEMI patients undergoing pPCI and IMR assessment



Fearon W, JACC 2008




### Clinical use of IMR

- Assessment of myocardial perfusion in STEMI patients
- Predictive value after primary PCI
- Assessment of microvascular damage after elective PCI

### Assessment of microvascular damage after elective PCI

- 50 patients randomized to conventional stenting with predilatation versus direct stenting
- IMR measured after PCI and correlated with troponin release



Cuisset T, JACC 2008




### Clinical use of IMR

- Assessment of myocardial perfusion in STEMI patients
- Predictive value after primary PCI
- Assessment of microvascular damage after elective PCI
- Assessment of pharmacologic strategies to prevent microvascular damage after elective PCI



### Assessment of pharmacologic strategies to prevent microvascular damage after elective PCI

#### ProMicro trial



Mangiacapra & Barbato, JACC 2013



### **Conclusions**

- Functional assessment of the coronary circulation enables the identification of the patients at increased risk of cardiovascular events
- With equivocal or absent objective evidence of vesselrelated ischemia, FFR measurement is recommended to guide revascularization
- The latter when adopted eventually translates into an improved clinical outcome of the patients